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The quality of sleep is significantly compromised in many patients with chronic obstructive
pulmonary disease (COPD) and may be further diminished when certain comorbidities are
present. A reduced sleep quality is associated with daytime consequences like fatigue,
psychiatric problems and an impaired quality of life.
Sleep induces physiologic alterations in respiratory function, which can become pathologic
and may provoke or worsen hypoxemia and hypercapnia in COPD. Dyspnea, cough and
excessive mucus production should be optimised to minimise causes for sleep disturbance.
Pharmacological therapy may be helpful; sedatives like benzodiazepines and non-
benzodiazepine benzodiazepine-receptor agonists (NBBRAs) are (equally) effective in
improving sleep quality. Whether or not these hypnotics produce serious adverse
respiratory effects during sleep, remains unclear due to opposing studies. Therefore,
their use should be as short as possible.
& 2008 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Chronic obstructive pulmonary disease (COPD) is a progres-
sive disease, which encompasses chronic obstructive bron-
chitis and emphysema and is associated with symptoms such
as dyspnea, cough and sputum production. The Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
defined COPD as ‘a preventable and treatable disease with
some significant extrapulmonary effects that may contribute
to the severity in individual patients.’1 Overall, the
management goals for COPD are improvement in quality of
life and in functional status in the absence of progression of
the disease.
Although COPD primarily affects the lungs, it also
produces significant systemic consequences, which can have
an important negative influence on the quality of life. These
systemic consequences include weight loss,2–4 muscle
wasting,5 cor pulmonale,6,7 pulmonary hypertension,8,9
excessive fatigue10,11 and sleep-related problems.10,12,13
This paper reviews the sleep-related problems in patients
with COPD and the effects of sleep on respiratory function.
The benefits and risks associated with the use of hypnotics in
patients with COPD will be discussed.
Sleep quality in patients with COPD
Already in 1976, it was reported that sleep is of poor quality
in patients with normoxemic COPD.14 Several years later,
significant disruptions of sleep in patients with hypoxemic
COPD were demonstrated in several studies.13,15,16 These
disruptions occurred simultaneously with oxygen desatura-
tions. Total sleep time (TST), amount of rapid eye move-
ment (REM) sleep and slow wave sleep (nREM stages 3/4)
were reduced and increases in the number of arousals and in
the number of sleep-stage changes per hour were de-
scribed.13,16 All these changes in sleep architecture haveadverse effects on the sleep quality. Figures 1 and 2 show,
respectively, examples of a normal hypnogram and a
hypnogram of a patient with COPD and severely disturbed
sleep.
The reduction in sleep quality results from a combination
of factors. Firstly, dyspnea is exaggerated in the supine
position, which causes delayed sleep onset and arousals.
Secondly, cough and excessive mucus production may
prolong sleep onset, especially because cough and mucus
production are exaggerated in the supine position. Thirdly,
the supine position results in altered ventilation/perfusion
(V/Q) relationships and subsequently nocturnal desatura-
tions and hypercapnia.17 Fourthly, the increased ventilatory
effort that patients with COPD have to deliver in response to
hypoxemia and/or hypercapnia, produces awakenings.18
Fifthly, the nocturnal desaturations and hypercapnic epi-
sodes themselves can cause arousals from sleep. A possible,
but uncertain sixth cause is the use of certain pulmonary
drugs that might affect sleep, like (oral) corticosteroids,19,20
b2-agonists,
21 anticholinergics22,23 and theophylline.24 The
use of these drugs in patients with sleep complaints will be
discussed later on.
Furthermore, it seems that a single night’s loss of sleep
results in significant, but clinically not relevant reductions
of forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC) in patients with COPD, as was shown by
Phillips et al.25 It is not known whether multiple nights of
sleep deprivation affect long-term pulmonary function.
Sleep-related complaints in patients with COPD
Insomnia, the most frequently reported sleep disorder,
is defined as difficulty falling asleep, difficulty staying
asleep, early awakening, or unrefreshing/nonrestorative
sleep in an individual who has adequate circumstances and
opportunity for sleep.26 Insomnia is associated with daytime
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Figure 1 Example of a normal hypnogram. This hypnogram shows how a typical night’s sleep for a healthy adult is organised. Notice
how the night is structured into the various stages of non-REM sleep alternating with REM sleep, with most slow-wave sleep occurring
in the first part of the night and most REM sleep occurring in the last part.
Sleep and COPD 803consequences like attention deficit, delayed reaction,
memory impairment, functional problems, frequent acci-
dents and risk of falls.27,28 Furthermore, patients with sleep
problems have higher rates of psychiatric and medical
illnesses, and insomnia is an important risk factor for the
development of depression, panic disorders and alcohol
abuse.29 Insomniacs also have higher rates of health care
utilization30 and reduced quality of life.28,31–34
Sleep-related complaints are ranked third, after dyspnea
and fatigue, in frequency of complaints of patients with
COPD.10 No relation was found between pulmonary function
and prevalence of sleep-related complaints. In the Tucson
Epidemiologic Study of Obstructive Airways Disease35 it was
found that 53% of patients with chronic bronchitis experi-
enced difficulties initiating and/or maintaining sleep (DIMS)
and 26% complained of excessive daytime sleepiness (EDS),
compared to 36% and 11%, respectively, in age-matched
subjects without any respiratory disease. In addition,
further analysis showed that the more pulmonary symptoms
a subject experienced during daytime, the higher the rate of
sleep complaints was. Also in this study there was no
relationship between lung function (FEV1/FVC ratio) and
prevalence of DIMS and EDS.12
In another study,13 patients with COPD (mean FEV1 0.88 l)
also reported more difficulty in getting to sleep and stayingasleep and had more daytime tiredness than age-matched
controls. Thirty-six percent of COPD patients had trouble
falling asleep and 28% of COPD patients reported use of
hypnotics compared to, respectively, 15% and 10% of the
patients without COPD.13
According to ERS/ATS guidelines,36 all patients with COPD
should be questioned about signs of sleep disorders such as
EDS, prolonged sleep latency and frequent arousals.
Physicians should be alert for the presence of a sleep
disorder when one or more of the following problems are
present: high blood pressure, breathing problems, urinary
problems, depression, chronic pain and gastrointestinal
problems.37,38
OSAS should be considered when symptoms like snoring,
EDS and witnessed apnoea during sleep occur. Other possible
causes for insomnia (i.e. comorbidities, drugs) should be
explored before any other step is taken to treat insomnia.
In summary, it seems that sleep-related complaints are
more prevalent among patients with COPD and that up to
50% of COPD patients experience problems during sleep. The
presence of sleep-related problems seems to have no
relationship with lung function,10,12,15 but they may have a
relationship with the frequency and severity of pulmonary
symptoms.12 All patients with COPD should be questioned
about symptoms of sleep disorders.
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Figure 2 Hypnogram of a patient with COPD and severely disturbed sleep.
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Sleep induces physiologic alterations in respiratory function,
which can become pathologic and may provoke or worsen
hypoxemia and hypercapnia. These alterations include
changes in the respiratory control centre,39 in airway
resistance,40,41 in functional residual capacity (FRC),42 in
V/Q relationships43 and in muscular contractility.44 During
sleep, the respiratory control centre is less sensitive and
responsive to chemical, mechanical and cortical input,
particularly during REM sleep.39,43,45 The ventilatory re-
sponse to hypercapnia and hypoxemia is mainly mediated by
‘‘chemical input’’ from chemoreceptors. Even in healthy
persons, the chemoreceptor response is blunted during
sleep compared with wakefulness, leading to a modest
increase in carbon dioxide tension (PCO2) of 2–6mmHg and a
marginal decrease in oxygen saturation (SaO2) of up to 2%
from baseline.46 In healthy adults the airway resistance
shows a circadian variation with the lowest resistance
around noon and a two-fold increase in the early morning
(3:00–6:00 h a.m.). Airflow resistance rose during sleep in
healthy subjects from 3.9 cmH2O during wakefulness to
7.9 cmH2O in stage 2 sleep and 8.6 cmH2O in REM sleep.
40
Peak flow rates drop an average of 8% during the night due
to this mild bronchoconstriction.47
This circadian variation is associated with an increased
cholinergic tone during sleep in the airway smooth mus-cle.22,48 There is also evidence that an imbalance between
both the magnitude and timing of electrical activity
between the upper airway and chest wall inspiratory
muscles exists during sleep.49,50 This could cause narrowing
of the upper airways. Other mechanisms, like an increase in
the levels of inflammatory mediators and steroids during
sleep, may also play a role.51
Functional residual capacity (FRC) is diminished during
both nREM and REM sleep in healthy humans and asthmatic
subjects, with the biggest decrease in the latter group.42,52
The causal mechanism for this decline in FRC is not clear,
but a reduced respiratory muscle contractility, cephalad
displacement of the diaphragm and a decrease in lung
compliance might be responsible.43 The impact of sleep on
FRC in patients with COPD has, to our knowledge, not been
studied yet. A reduced FRC results in a closing of small
airways and this leads to V/Q mismatching in these areas.43
Respiratory muscle function is impaired during sleep,
particularly during REM sleep.44 Ventilation largely depends
on diaphragm function during REM sleep, due to reductions
in electromyographic activity of the upper airway muscles,
intercostal muscles and other accessory muscles during
phasic REM sleep compared to non-REM sleep.53,54 The
reduction in the intercostal and other accessory muscle
activity leads to a decrease in rib cage contribution to
ventilation.54,55 During REM sleep the ribcage contribution
to tidal volume fell from 44% to 19% of the tidal volume.54
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Sleep and COPD 805The upper airway dilator muscle function is also compro-
mised, which can cause ‘obstructive’ hypopnoea.50
In healthy humans these physiologic changes, and not the
respiratory rate, are responsible for a 6% reduction in
inspired minute ventilation (Vi) during nREM sleep compared
to wakefulness, with a concomitant increase of PCO2 of
2–4mmHg.56–59 During REM sleep Vi further decreases by 16%
compared to wakefulness.46
Similar changes in respiratory function occur during sleep
in patients with COPD as in healthy subjects, although some
can be more profound in COPD. It was shown that in patients
with COPD respiratory control centre output was reduced
and upper airway resistance was increased, both most
severely during REM sleep.60 The circadian variation in
airflow is exaggerated in patients with COPD.61–63 A mean
daily FEV1 variation of 286ml was found, which was a 30%
circadian change in FEV1.
61 A parallel circadian change in
FVC was noticed in this study with no meaningful change in
the FEV1/FVC ratio. The occurrence of V/Qmismatching was
suggested following the observation of a relative greater fall
in nocturnal SaO2 than a rise in transcutaneous PCO2 in some
patients with COPD during sleep.64
Muscular contractility is already reduced during daytime
in patients with COPD and this is aggravated during sleep.53
The function of the diaphragm is even more decreased than
in healthy subjects because it is flattened due to hyperin-
flation and therefore relatively inefficient.39 The relatively
large dependency on diaphragm function during sleep might
explain why patients with loss of respiratory muscle strength
show nocturnal desaturations.65 Sleep has a more pro-
nounced effect on Vi in patients with COPD than in healthy
humans. A decrease in Vi of 16% during nREM sleep and a
decrease of 32% during REM sleep compared to wakefulness
were reported in patients with COPD, whereas the Vi
remained practically unchanged during sleep and wakeful-
ness in healthy humans.59
In patients with COPD, these changes during sleep may
have a more profound effect on gas exchange and can cause
severe hypoxemia and hypercapnia, especially during REM
sleep, as was shown by several authors.14,66–70 One study68
showed a maximum fall in arterial oxygen tension (PaO2) of
3.5 kPa during REM sleep in patients with COPD. Another
study69 concluded that disordered breathing during sleep is
common in patients with COPD and often causes desatura-
tions (mean desaturation of 7.6% from baseline) due to
apnoeas and hypoventilation. Forty-two percent of the
desaturations during sleep could be explained by simulta-
neously occurring disordered breathing. The prevalence of
nocturnal desaturations (SaO2 drop 44% from baseline) was
present in 78% of the COPD patients in our own study.70 These
desaturations during sleep may be greater than during
maximum exercise.64 Hypoventilation during sleep in COPD
patients, and its consequences on gas exchange, might
contribute to the development of chronic daytime hypercap-
nia, cardiac arrhythmias,71 myocardial ischemia,72 pulmonary
hypertension,73 cor pulmonale74 and even nocturnal death.75Sleep in patients with COPD and comorbidities
Several diseases other than COPD may cause disordered
breathing during sleep. When these diseases co-exist withCOPD, they have the potential to induce or aggravate
hypoventilation during sleep. These are for example the
obstructive sleep apnoea syndrome (OSAS), neuromuscular
disorders like muscular dystrophies, restrictive lung dis-
orders and cardiovascular disorders like congestive heart
failure and atrial fibrillation.
The prevalence of OSAS is not higher in patients with
(mild) COPD than in a comparable group of patients without
COPD.76 Therefore, the appearance of COPD and OSAS in one
individual (overlap syndrome) appears by chance without
any pathophysiologic linkage. Patients with this overlap
syndrome had more severe desaturations during sleep and
worse sleep quality than patients with only one of these
disorders.76 They are also more likely to develop pulmonary
hypertension,77 right heart failure78 and hypercapnia79 than
patients with one disorder.
No data are available on nocturnal respiratory function in
patients with COPD and co-existing neuromuscular disor-
ders, restrictive lung disorders or cardiovascular disorders.
Other frequently co-existing diseases or used medication,
which do not necessarily influence respiration, may them-
selves cause or aggravate sleep disorders. These disorders
include diabetes mellitus,80 thyroid diseases, hypertension81
and psychiatric disorders amongst others. Non-pulmonary
drugs which may induce or aggravate sleep disorders are for
instance, anticonvulsants, analgesics, antidepressants, beta
adrenergic blockers, diuretics, thyroid preparations, caf-
feine and alcohol.82
Physicians should take notice that not only the usage, but
also the discontinuation of these drugs may cause sleep
disorders.Treatment of sleep-related complaints
Treatment of sleep-related complaints may vary according
to the severity and other co-existing health problems and
can be composed of non-pharmacological,83–85 pharmacolo-
gical therapy or both.86–88Non-pharmacological therapy
Non-pharmacological therapies produce long-lasting and
reliable changes and have minimal side effects in people
with chronic insomnia without COPD.88,89 They include
education, sleep hygiene, stimulus control, sleep restric-
tion, relaxation techniques, biofeedback, paradoxical in-
tention and cognitive behaviour therapy.88 The non-
pharmacological management of insomnia concentrated on
patients with COPD has not been subject to study yet.
Nevertheless, sleep quality in patients with COPD might
improve when non-pharmacological therapy is focussed on
measures to minimise the previously mentioned causes for
sleep disturbance, i.e. on measures to limit dyspnea, cough
and excessive mucus production.
In several studies,15,90–92 the effect of oxygen supple-
mentation on sleep quality in patients with COPD was
investigated. Two of these studies90,91 found improvements
in sleep quality, where the other two15,92 did not. Due to
methodological differences like randomisation and study
populations, these studies are difficult to compare.
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Pulmonary medication
The b2-agonist salbutamol did not affect sleep quality and
nocturnal oxygenation in patients with asthma and COPD.21
Studies on the effects of other b2-agonists on sleep quality
are not available. The anticholinergic ipratropium was
shown to beneficially influence sleep quality and SaO2
during sleep in patients with moderate to severe COPD.22
The number of awakenings per hour of sleep also improved
with ipratropium in this study, and the authors discussed
that ipratropium might beneficially influence a pre-existing
imbalance in the autonomic nervous system which may be
the underlying cause for nocturnal dyspnea and sleep
disturbance. In another study23 the long-acting anticholi-
nergic tiotropium improved nocturnal oxygen saturation but
did not affect sleep quality. Data on the effects of (inhaled)
corticosteroids on sleep are sparse. In one study,19 a single
dose of 60mg prednisone taken orally reduced the amount
of REM sleep and prolonged the REM sleep latency in healthy
subjects. Dosages of 5 and 20mg prednisone had no
significant effects on sleep quality in this study. What the
effect is of repeated doses of inhaled steroids on sleep is
unclear, but in view of its local administration and relatively
small amounts, it will perhaps be negligible.
The methylxanthine theophylline has been associated
with sleeping complaints due to its chemical resemblance to
caffeine (1,3,7-trimethylxanthine). In healthy normal in-
dividuals it disturbs sleep quality by prolonging sleep
latency, increasing the arousal frequency, reducing TST and
increasing the amount of stage 1 sleep.93,94 Objective
studies in patients with COPD24,95,96 have shown that it
does not worsen sleep quality in these patients, and one
study24 even found an improvement in sleep quality. It is
likely that the therapeutic effect of theophylline on lung
function outweighs the adverse effects on sleep.
In summary, none of the commonly used pulmonary
medications are proven to adversely influence sleep quality
and the anticholinergic ipratropium may even improve sleep
quality.
Hypnotics
Drug therapy is indicated only when sleep-related com-
plaints influence daytime functioning and when non-phar-
macologic measures are insufficient to relieve a patient’s
insomnia. In these cases drug therapy is recommended only
for a short period of time. In theory, this means that
hypnotics should not be used very often and for 4 weeks
maximum. In practice however, hypnotic drugs are fre-
quently prescribed and often on a long-term basis.
The most common medications used to promote sleep
are the benzodiazepine-receptor agonists (benzodiazepines
and non-benzodiazepine benzodiazepine-receptor agonists
(NBBRAs)). Other agents that are presently used for insomnia
include sedating antidepressants and over-the-counter sleep
products like antihistamines and melatonin-receptor agonists.
Benzodiazepines and NBBRAs
Some community-based surveys showed benzodiazepines
being the most frequently prescribed drug in the general
population.97 Reported prevalence rates of benzodiazepineuse range from 2.2% to 17.6%.98,99 This wide variation in
rates can be explained by differences in definitions and
observation periods.
There is only one report on the usage of hypnotics in
COPD patients.13 In this study 28% of the COPD patients
compared to 10% in the control group (patients with a
chronic non-lung disease) regularly used a hypnotic. Other
studies on the quantity of prescription of hypnotics, and
especially benzodiazepines, in patients with COPD are not
available.Mechanism of action and side effects
In healthy individuals, benzodiazepines improve sleep
quality by increasing TST and reducing the latency to sleep
onset.100,101 They affect sleep architecture by increasing
the percentage of stage 2 sleep and decreasing the
percentage of stages 1 and 3–4 sleep and REM sleep.102
The precise mechanism of the hypnotic effect is not entirely
understood. Benzodiazepines are suspected to bind to the
benzodiazepine-receptors (o-receptors) of the GABAa–re-
ceptor–chloride complex. By doing so, the affinity of this
complex for GABA is enhanced. Binding of GABA opens
chloride-channels, which causes hyperpolarisation of differ-
ent cell membranes and subsequently inhibition of neuro-
transmission, which results in sleepiness, anxiolysis, an
anticonvulsant effect and skeletal muscle relaxation.
Benzodiazepines differ from each other by their duration
of action and pharmacokinetics and can be divided in short-
acting (half-lifeo5 h: brotizolam, triazolam), intermediate-
acting (half-life45, o24 h: temazepam, estazolam, loraze-
pam, oxazepam) or long-acting (half-life424 h: nitrazepam,
flurazepam, diazepam, quazepam) agents.
NBBRAs like zaleplon, zopiclone and its isomer eszopi-
clone, zolpidem and alpidem (respectively, being a pyrazo-
lopyrimidine, a cyclopyrrolone and the latter two being
imidazopyridines) are non-benzodiazepines, which also bind
to benzodiazepine-receptors and exhibit similar effects with
some differences from benzodiazepines in pharmacological
effects and mechanisms of action. They have short half-lives
(3–5 h) and short durations of action compared with most of
the benzodiazepines.Beneficial effects
Many randomised trials have shown the efficacy of benzo-
diazepines103–106 and NBBRAs107–111 in relieving short-term
insomnia and only in 2003 the first long-term efficacy trial112
was published. In Table 1, the results of different meta-
analyses86,100,101,113,114 are pooled together.
Besides their previously described effects on sleep
architecture, benzodiazepines and NBBRAs produce signifi-
cant improvements in TST, subjective sleep latency, number
of awakenings, and subjective sleep quality. Short-acting
agents had larger effects on sleep latency than on TST, while
the longer-acting benzodiazepines mainly influenced the
TST. There was no difference in hypnotic effect between
benzodiazepines and zolpidem, although no subgroup-
analysis (for short-, intermediate- and long-acting drugs)
was performed.
In a meta-analysis (n ¼ 3909 subjects), the clinical
effectiveness of NBBRAs and benzodiazepines was compared.101
They concluded that there are only minor differences in
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Table 1 Findings of meta-analyses regarding the efficacy and safety of benzodiazepines and NBBRAs.
Source No. of
subjects
Age
(years)
Compared drugs Main conclusions
Du¨ndar et al.101 3909  Benzodiazepines  All short-acting hypnotics are equally effective
for insomnia
 Equally safe
 Only minor differences between the drugs,
probably due to pharmacokinetics
NBBRAs
Glass et al.113 1072 460 Antihistamines When compared to placebo, sedatives
 Produced significant but small improvements in
sleep quality
(NNT: 13 for improved sleep quality)
 Gave more adverse effects (NNT: 6 for adverse
effects)
Benzodiazepines
NBBRAs
Holbrook et al.100 2672 29–82 Antihistamines When compared to placebo, sedatives
 improved sleep quality (TST increased 62min)
 gave more adverse effects (OR 1.8)
When compared amongst one another,
 benzodiazepines and zolpidem are equally
effective and safe
Benzodiazepines
Gluthetimide
Zopiclone
Nowell et al.114 1894 18–65 Benzodiazepines When compared to placebo, sedatives
 improved objective and subjective sleep quality
 adverse effects
Zolpidem
Smith et al.86 470 47.2 Benzodiazepines When compared to placebo, sedatives
 improved objective and subjective sleep quality
When compared with behavioural therapy, sedatives
 showed comparable efficacy
Adverse effects
NBBRAs
NBBRA, non-benzodiazepine benzodiazepine-receptor agonist; NNT, number needed to treat; NS, not significant; OR, odds ratio; TST,
total sleep time.
Not reported.
Sleep and COPD 807efficacy between the NBBRAs and between NBBRAs
and benzodiazepines, which were difficult to quantify
and evaluate, mainly due to limitations in available
research.
An interesting observation was noticed by Greene et al.115
They saw improvements in dyspnea and alertness after
alprazolam administration to a 50-year-old male with
a1-antitrypsin deficiency.
Adverse effects
Besides beneficial effects, all hypnotics show in one way or
another unfavourable effects. The previously mentioned
meta-analysis100 reported benzodiazepines to cause com-
plaints of daytime drowsiness, dizziness and light head-
edness. Other adverse effects include dependence,116
rebound anxiety and rebound insomnia, memory impair-
ment,116 withdrawal reactions,116 a risk of falling associated
with muscle hypotonia117,118 and pneumonia.119
NBBRAs show the same range of undesirable effects, and
as well as in benefits they show only distinct differences in
the magnitudes of adverse effects.101Furthermore, benzodiazepines and NBBRAs have exten-
sively been studied for their effects on breathing during
sleep, both in healthy individuals (Table 2), in patients with
COPD (Table 3) and once in elderly patients with sleep
apnoea.120 Most, but not all studies were performed during
sleep. Medications studied included alprazolam,115 brotizo-
lam,121 diazepam,122–126 estazolam,127 flurazepam,127–130
flunitrazepam,102,131–133 lorazepam,134 midazolam,124 nitra-
zepam,133,135 temazepam,120 triazolam,102,131,132,136–138 za-
leplon,139 zolpidem123,131,132,137,139–143 and zopiclone.122,125,144
Some of these studies (using diazepam, flunitrazepam,
flurazepam, lorazepam, nitrazepam, triazolam, zolpidem
and zopiclone) found that these drugs decrease central
respiratory drive, increase upper airway resistance,
particularly by acting on upper airway dilators (genioglossus
muscles), decrease the arousal response, decrease respi-
ratory muscle strength, and increase sleep-disordered
breathing. Adverse effects were expressed as an increase
in the number of apnoeas, prolongation of occurring
apnoeas, increase in the degree of desaturation, depression
of the CO2 ventilatory response, increase in breathing
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airway occlusion and increase in respiratory effort (accord-
ing to rise in end-expiration oesophageal pressure).
These unfavourable effects were present both in healthy
subjects and patients with COPD, and although most results
were significant, the magnitudes were small.
Opposing results, again present both in healthy subjects
and patients with COPD, are available from a comparable
amount of other studies120,121,123,124,126,129,133,137,138,140
(Tables 2 and 3). These studies also focused on the
respiratory effects of hypnotics (using alprazolam, brotizo-
lam, diazepam, midazolam, flunitrazepam, flurazepam,
nitrazepam, zaleplon, zolpidem and zopiclone), but could
not find any adverse effects. Although Steens et al.137 foundTable 2 Findings of studies regarding the adverse effects of b
Source No. of
subjects
Drug, dose Length
drug u
Beaumont et al.139 12 Zaleplon 1 night
Zolpidem
Beaumont et al.140 8 Zolpidem 1 night
Berry et al.136 6 Triazolam 0.25mg 1 night
Cohn121 12 Brotizolam 0.5mg 6 h
Cohn142 12 Zolpidem
10.20mg
3 h
Codeine
phosphate 60mg
Dolly and Block130 20 Flurazepam 30mg 1 night
Maillard et al.123 16 Diazepam 10mg 3 h
Zolpidem
10.20mg
Mak et al.124 6 Diazepam 5mg 1 h
Midazolam 7.5mg
McCann et al.141 10 Zolpidem 10mg 1 night
Ranlov and
Nielsen125
10 Diazepam 10mg 1 day
Zopiclone 7.5mg
Schneider et al.102 24 Triazolam 0.25mg 1 night
Flunitrazepam
2mg
AE, adverse effects; ABG, arterial blood gas; COPD, chronic obstructiv
forced vital capacity; HCVR, hypercapnic ventilatory response; HVR
index; SaO2, arterial oxygen saturation; SDB, sleep-disordered breatno differences in arterial oxygen saturation and apnoea–-
hypopnoea index after zolpidem, triazolam or placebo use in
24 subjects with COPD (mean FEV1 61%), they felt that
‘caution is still required when these hypnotics are pre-
scribed to these patients.’
Several problems occur when interpreting these studies.
One problem with most of these studies is their limited
duration. Due to short study periods of only a few nights or
even only one night, carry-over effects were often not
measured. A second problem is the inclusion of subjects with
a varying severity of COPD. Thirdly, none of the available
studies was performed in COPD patients while they had
an exacerbation, although it could be hypothesised, that
during an exacerbation more severe sleeping problemsenzodiazepines and NBBRAs in healthy subjects.
of
se
Conclusions
 No AE on respiration
 No AE on respiration
 AE on arousal threshold
 No AE on circulatory and respiratory
parameters (pulse, blood pressure, FEV1, FVC,
respiratory rate, mouth occlusion pressure and
HCVR)
 AE: 20mg zolpidem decreased inspiratory flow
 No AE on respiratory parameters after 10mg
zolpidem
 AE: codeine phosphate decreased HCVR and
mouth occlusion pressure
 AE on SDB and SaO2-levels
 No AE on Vt and mouth occlusion pressure
 No AE on Ve, HCVR and HVR
 No AE on RDI and SaO2-levels
 HCVR reduced after diazepam, not with
zopiclone
 No AE in ABG, Vt, Ve and breathing frequency
 No AE on RDI and desaturation-index
 Increase in breathing frequency
 Increase in oesophageal pressure
e pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC,
, hypoxemic ventilatory response; RDI, respiratory disturbance
hing; Ve, minute ventilation; Vt, tidal volume.
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Table 3 Overview of studies regarding the adverse effects of benzodiazepines and NBBRAs in patients with COPD.
Source No. of
subjects
Severity of
COPD
Drug, dose Length of
drug use
Conclusions
Beaupre et al.122 32 Moderate
to severe
Diazepam 1 day  AE: diazepam increased PetCO2
 AE: zopiclone increased breathing
frequency
 No differences between the two drugs
Zopiclone
Block et al.128 20 FEV1 1–2 l Flurazepam 30mg 1 night  AE on SDB and SaO2-levels
Cohn et al.127 29 Mild Flurazepam 30mg 5 days  AE: flurazepam decreased Vt and SaO2 and
increased breathing frequency
 No AE on HCVR
Estazolam 2mg
Cummiskey et al.129 5 Mild Flurazepam 15 and
30mg
7 nights  No AE on respiratory parameters
Girault et al.143 10 Mean FEV1
0.84 l
Zolpidem 9 nights  No AE
Greene et al.115 1 Mild Alprazolam 0.5mg 8h  Case report: no AE on respiratory
parameters
Jolly et al.134 9 Mean FEV1
0.9 l
Lorazepam
1.5–2mg
1h  AE on VE and respiratory muscle strength
Midgren et al.133 14  Nitrazepam 5mg 1 night  No AE on respiratory parameters
Flunitrazepam
1mg
Muir et al.144 6 Severe Zopiclone  No AE on respiratory parameters
Murciano et al.132 9 Severe Triazolam 0.25mg 2h  AE: flunitrazepam increased PaCO2 and
decreased Ve
 No AE on ABG, mouth occlusion pressure,
HCVR with triazolam and zolpidem
Flunitrazepam
1mg
Zolpidem 10mg
Murciano et al.131 12 Mean
predicted
FEV1 32%
Triazolam 0.25mg 2h  No AE on ABG, mouth occlusion pressure,
HCVR with zolpidem
 AE: flunitrazepam and triazolam increased
PaCO2 and decreased Ve
Flunitrazepam
1mg
Zolpidem 10mg
Rudolf et al.135  Nitrazepam 10mg Repeated
nights
 AE: increase PaCO2 in hypercapnic
patients
Steens et al.137 24 Mean
predicted
FEV1 61%
Triazolam 0.25mg 1 night  No AE on SaO2 and RDI
 No differences between triazolam and
zolpidem
Zolpidem 5 and
10mg
Timms et al.138 10 FEV1
17–76%
Triazolam 0.125
and 0.25mg
1 night  No AE on desaturation-index and RDI
Wedzicha et al.126 9  Diazepam 5mg 1 night  Sleep duration improved
 No AE on nocturnal hypoxaemia and the
number of apneic events
ABG, arterial blood gas; AE, adverse effects; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s;
HCVR, hypercapnic ventilatory response; PaCO2, arterial carbon dioxide tension; PetCO2, end-tidal carbon dioxide tension; RDI,
respiratory disturbance index; SaO2, arterial oxygen saturation; SDB, sleep-disordered breathing; Ve, minute ventilation; Vt, tidal
volume.
Not reported.
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pines with different pharmacodynamics, which makes these
studies even more difficult to compare. Moreover, various
respiratory parameters have been used to evaluate respira-
tory function, what makes the comparison also more
troublesome.
None of these studies mention the presence or absence of
sleep-related problems in their subjects, so it is not known if
these results can uniformly be applied to patients with and
without sleep-related problems and those with sleep-
related problems are precisely the patients one might
prescribe a hypnotic to. Furthermore, only one study127
evaluated effects (adverse as well as beneficial) of ante
noctem benzodiazepines during daytime.
Benzodiazepines vs. NBBRAs
Six studies122,123,125,131,132,137 compared the respiratory
effects of NBBRAs and benzodiazepines with each other.
Five of these studies were performed in patients with COPD
and three of these122,131,132 reported adverse respiratory
effects. Only one author found in two similar studies that a
long-acting benzodiazepine (flunitrazepam increased PaCO2
and decreased Ve) had more unfavourable effects on
respiration than a short-acting benzodiazepine (triazolam)
and a NBBRA (zolpidem). The other four studies all reported
no differences in adverse respiratory effects between
benzodiazepines and NBBRAs. To date, a meta-analysis on
this subject has not been carried out, but could be helpful to
interpret these contrasting reports.
Alternative sedatives
Sedating antidepressants, antihistamines, melatonin and
other over-the-counter drugs like 5-hydroxytryptophan, St.
John’s Wort and valerian root are sometimes used in the
treatment of insomnia. The use of these alternatives rather
than benzodiazepines and NBBRAs for the pharmacological
treatment of insomnia is not supported by available
evidence in healthy subjects or in patients with COPD.145,146
The occurrence of respiratory adverse effects associated
with these drugs has been subject of a few studies,147–149
but without evidence for their efficacy in insomnia, more of
these studies will probably not be needed.
Discussion and conclusion
Overall, one can conclude that (a) NBBRAs and benzodiaze-
pines both improve sleep quality, whereas alternative
hypnotics fail to do so; (b) NBBRAs and benzodiazepines
seem to be equally effective in treating insomnia; (c) short-
acting agents mainly improve subjective and objective sleep
latency while longer acting agents mainly improve TST;
(d) all NBBRAs and benzodiazepines can produce undesirable
effects like drowsiness, dependence, rebound insomnia
and memory impairment; (e) regarding adverse effects
only distinct differences exist between NBBRAs and benzo-
diazepines; (f) in healthy subjects four studies reported
modest adverse respiratory effects associated with benzo-
diazepines and NBBRAs, where six other studies did not; (g)
seven studies with patients with COPD showed adverse
respiratory effects associated with NBBRAs and benzodiaze-
pines, where seven others did not and (h) comparisonstudies showed no significant differences in benefits and
adverse effects between short acting benzodiazepines and
NBBRAs but more adverse effects were seen with longer
acting benzodiazepines.
Obviously, a meta-analysis is needed but is difficult to
carry out due to the wide variation in available studies.
Benzodiazepines may have some adverse effects on respira-
tory function in healthy people, although these effects may
only be very moderate and therefore could be tolerated in
this population. Comparable changes are seen in patients
with COPD, but it remains unclear if these can be tolerated
as well. Consequently, the use of benzodiazepines in these
patients should be as short as possible.
ERS/ATS guidelines36 state that ‘hypnotics, particularly
benzodiazepines, should be avoided, if possible, y,
although there is evidence that some hypnotics, such as
zolpidem, can be used in less severe COPD without
significant adverse effects on gas exchange.’ This statement
is partially in contrast to the findings in this review, because
(a) several studies failed to show deleterious effects on
respiration from hypnotics and (b) as written above,
comparison studies showed no significant differences be-
tween short acting benzodiazepines and NBBRAs.
Physicians should keep in mind that up to 50% of their
patients with COPD experience sleep abnormalities. By
asking for sleeping complaints and understanding the
pathophysiology and available treatment options for these
problems, they have a great tool to substantially improve
their patients’ quality of life. Therefore, more research
is needed on the usage of sleep medication in patients
with COPD.
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